Several studies reported that DNA methyltransferase (DNMT) inhibitors decitabine and azacytidine could increase PD-L1 expression level and enhance anti-PD-1 Ab therapeutic efficacy in tumor cells (16–18). This evidence concerns the gene CD274 and neoplasm.